论文部分内容阅读
目的:观察婴幼儿巨细胞病毒性肝炎患儿应用更昔洛韦治疗的临床效果。方法:选取我院收治的60例患有巨细胞病毒性肝炎的婴幼儿,按照随机数字表法分为试验组和安慰剂组,每组30例。试验组给予更昔洛韦治疗,分为诱导期及维持期治疗。诱导期给予更昔洛韦5 mg/kg加入10%葡萄糖注射液100 mL中静脉滴注,每日2次,诱导期疗程为14 d;后进入维持期治疗,应用更昔洛韦5 mg/kg加入10%葡萄糖注射液100 mL中,每日1次静脉滴注,疗程14 d。安慰剂组给予形态、外观与试验组一致的安慰剂药物。分析比较使用更昔洛韦治疗前后患儿的症状及各项临床生化指标检查结果。结果:治疗后所有患儿临床症状均显著改善;安慰剂组患儿CMV-IgM转阴率为56.67%,试验组为83.33%,两组比较差异有统计学意义(P<0.05);试验组较安慰剂组患儿的谷丙转氨酶(GPT)及总胆红素(TBIL)显著降低(P<0.05);治疗过程中不良反应轻微。结论:更昔洛韦治疗婴幼儿巨细胞病毒性肝炎安全有效。
Objective: To observe the clinical effect of ganciclovir in infants with cytomegalovirus hepatitis. Methods: Totally 60 infants and children with cytomegalovirus hepatitis treated in our hospital were divided into experimental group and placebo group according to the random number table method, with 30 cases in each group. The experimental group was treated with ganciclovir, divided into induction and maintenance treatment. Induction period given ganciclovir 5 mg / kg by adding 10% glucose injection 100 mL intravenous infusion twice daily, induction period of 14 days; after entering the maintenance period of treatment, the application of ganciclovir 5 mg / kg added 10% glucose injection 100 mL, daily intravenous infusion, treatment 14 d. The placebo group was given a placebo drug whose appearance was the same as that of the test group. Analysis of the use of ganciclovir before and after treatment in children with symptoms and various clinical and biochemical indicators test results. Results: The clinical symptoms of all children were significantly improved after treatment. The negative rate of CMV-IgM in placebo group was 56.67% and the rate of CMV-IgM was 83.33% in the placebo group. The difference between the two groups was statistically significant (P <0.05) Compared with placebo group, GPT and total bilirubin (TBIL) were significantly decreased (P <0.05); adverse reactions during treatment were mild. Conclusion: Ganciclovir is safe and effective in the treatment of infantile cytomegalovirus hepatitis.